Intensity Therapeutics (INTS) vs Phio Pharmaceuticals (PHIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Intensity Therapeutics (INTS) has outperformed Phio Pharmaceuticals (PHIO) over the past year, losing 48.4% versus a loss of 59.8%. Intensity Therapeutics is the larger company by market cap ($12.0 million vs $11.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INTS | PHIO |
|---|---|---|
| Share price | $3.68 | $0.9731 |
| Market cap | $12.01M | $11.30M |
| 1-day change | -3.16% | -2.69% |
| YTD return | -64.10% | -7.32% |
| 1-year return | -48.35% | -59.79% |
| 5-year return | — | -99.46% |
| EPS (TTM) | $-3.89 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.50 | $4.19 |
| 52-week low | $3.21 | $0.813 |
| Distance from 52-week high | -91.54% | -76.78% |
| Analyst consensus | none | none |
| Avg. price target upside | +425.27% | +1338.70% |
| Average volume | 25.93K | 582.32K |
| Shares outstanding | 3.26M | 11.62M |
| Employees | 5 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INTS has outperformed PHIO by 11.4 percentage points over the past year.
About Intensity Therapeutics
INTS stock →Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About Phio Pharmaceuticals
PHIO stock →Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
INTS vs PHIO FAQ
Which is bigger, Intensity Therapeutics or Phio Pharmaceuticals?
Intensity Therapeutics (INTS) is larger, with a market capitalization of $12.01M compared with $11.30M for Phio Pharmaceuticals (PHIO).
Which stock has performed better over the past year, INTS or PHIO?
INTS returned -48.35% over the past 12 months, compared with -59.79% for PHIO (price return, excluding dividends). Past performance does not predict future results.
Are Intensity Therapeutics and Phio Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Intensity Therapeutics and Biotechnology: Pharmaceutical Preparations for Phio Pharmaceuticals.